Hyderabad, India

Dr. Reddy's Laboratories

Indian pharmaceutical company listed in India and on the New York Stock Exchange. It makes generic semaglutide injection and launched it in India in March 2026 and in Canada in 2026. Its filings say it produces the active ingredient in-house. In July 2026 it disclosed that certain batches were out of specification because of an issue with the active ingredient, and that commercial supplies would be delayed. Statements below are the company's own, taken from its filings with the SEC.

India launch (March 2026)

On 21 March 2026 Dr. Reddy's announced the launch in India of 'Obeda', which it described as India's first DCGI-approved semaglutide injection, for type 2 diabetes. The company said a head-to-head Phase 3 study of 312 participants showed non-inferior efficacy and similar safety compared with the innovator drug, and that both the active ingredient and the formulation were developed in-house.[src]

Canada approval (April 2026)

On 29 April 2026 Dr. Reddy's announced that Health Canada had issued a Notice of Compliance for its generic semaglutide injection. The company said it was the first company to receive market authorisation for generic semaglutide injection in Canada, that the active ingredient is produced in-house, and that finished-product manufacturing is carried out by its partner OneSource Specialty Pharma Limited.[src]

Out-of-specification batches (July 2026)

On 9 July 2026 Dr. Reddy's disclosed that certain batches of semaglutide were found to be out of specification due to an issue associated with the active pharmaceutical ingredient used in the product, and that commercial supplies would be delayed until the issue is resolved. The company said there was no impact on patient safety or on the product's existing global regulatory filings.[src]

First quarter FY2027 results (July 2026)

For the quarter ended 30 June 2026 Dr. Reddy's reported revenue of INR 80,705 million, down 5.6% from a year earlier. The results include a provision of INR 2,397 million for inventory and other associated costs related to the semaglutide active ingredient.[src]